Akiko Koide

US Patent:

20220340666, Oct 27, 2022

Filed:

Jun 28, 2022

Appl. No.:

17/851947

Inventors:

- New York NY, US
- Boston MA, US
Akiko Koide - New York NY, US
Linxiao Chen - Doylestown PA, US
Eric Elenko - Boston MA, US
Aleksandra Filipovic - London, GB
Joseph Bolen - Boston MA, US

International Classification:

C07K 16/28
A61P 35/00
C07K 16/06
A61P 37/06

Abstract:

Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

US Patent:

20220332830, Oct 20, 2022

Filed:

Jun 28, 2022

Appl. No.:

17/851930

Inventors:

- New York NY, US
- Boston MA, US
Akiko Koide - New York NY, US
Linxiao Chen - Doylestown PA, US
Eric Elenko - Boston MA, US
Aleksandra Filipovic - London, GB
Joseph Bolen - Boston MA, US

International Classification:

C07K 16/28
A61P 35/00
C07K 16/06
A61P 37/06

Abstract:

Disclosed herein are anti-Galectin-9 antibodies and methods of using such for inhibiting a signaling pathway mediated by Galectin-9 or eliminating pathologic cells expressing Galectin-9. Such anti-Galectin-9 antibodies may also be used to diagnose and/or to treat diseases associated with Galectin-9, such as autoimmune diseases and solid tumors.

US Patent:

20220332832, Oct 20, 2022

Filed:

Aug 3, 2020

Appl. No.:

17/631378

Inventors:

- New York NY, US
- Boston MA, US
Akiko KOIDE - New York NY, US
Linxiao CHEN - New York NY, US
Aleksandra FILIPOVIC - London, GB
Eric ELENKO - Boston MA, US
Joseph BOLEN - Boston MA, US

International Classification:

C07K 16/28
A61P 37/06
A61P 35/00

Abstract:

Combined therapy for a solid tumor, comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g, G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.

US Patent:

20220259304, Aug 18, 2022

Filed:

Dec 30, 2021

Appl. No.:

17/565994

Inventors:

- New York NY, US
- Ghent, BE
Akiko KOIDE - New York NY, US
Nadia LELOUP - New York NY, US
Julien OURY - New York NY, US
Karen SILENCE - Ghent, BE
Roeland VANHAUWAERT - Ghent, BE
Christophe BLANCHETOT - Ghent, BE

International Classification:

C07K 16/28
A61P 21/04

Abstract:

The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.

US Patent:

20220204629, Jun 30, 2022

Filed:

Mar 25, 2020

Appl. No.:

17/598215

Inventors:

- New York NY, US
- Boston MA, US
Akiko KOIDE - New York NY, US
Linxiao CHEN - New York NY, US
Aleksandra FILIPOVIC - London, GB
Eric ELENKO - Boston MA, US
Joseph BOLEN - Boston MA, US

International Classification:

C07K 16/28
A61K 39/395
A61K 31/7068
A61K 31/337
A61P 35/00

Abstract:

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

US Patent:

20220185896, Jun 16, 2022

Filed:

May 1, 2020

Appl. No.:

17/607878

Inventors:

- New York NY, US
- Boston MA, US
Akiko KOIDE - New York NY, US
Linxiao CHEN - New York NY, US
Aleksandra FILIPOVIC - London, GB
Eric ELENKO - Boston MA, US
Joseph BOLEN - Boston MA, US

International Classification:

C07K 16/28
A61P 35/04
A61P 35/00

Abstract:

Disclosed herein are methods for treating solid tumors (e.g., pancreatic adenocarcinoma (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC)), or Cholangiocarcinoma and others), including, but not limited to, metastatic tumors, using an anti-Galectin-9 antibody.

US Patent:

20220177531, Jun 9, 2022

Filed:

Dec 6, 2021

Appl. No.:

17/543464

Inventors:

- New York NY, US
Kai Wen Teng - Flushing NY, US
Akiko Koide - New York NY, US
Takamitsu Hattori - West New York NJ, US

International Classification:

C07K 14/47
A61P 35/00

Abstract:

Provided are proteins or peptides, which may be referred to as monobodies. Fusion proteins and proteolysis targeting chimeras (PROTACs) comprising the proteins or peptides are also provided. Also provided are compositions of the proteins or peptides of the present disclosure, as well as compositions of fusion proteins and compositions of PROTACs. Methods of treating an individual in need of treatment are also provided. The methods may be to treat an individual suffering from or suspected of having KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers. A method may be for inhibiting ERK activation and/or proliferation of KRAS(G12V), KRAS(G12S), KRAS(G12A) and/or KRAS(G12C)-associated cancers.

US Patent:

20220178930, Jun 9, 2022

Filed:

May 1, 2020

Appl. No.:

17/607879

Inventors:

- New York NY, US
- Boston MA, US
Akiko KOIDE - New York NY, US
Linxiao CHEN - New York NY, US
Aleksandra FILIPOVIC - London, GB
Eric ELENKO - Boston MA, US
Joseph BOLEN - Boston MA, US

International Classification:

G01N 33/574
C07K 16/28

Abstract:

Disclosed herein are methods for identifying a subject as having certain solid cancers such as breast cancer, colorectal colon cancer, or non-small cell lung cancer, or being at risk for the cancer based on the level of Galectin-9 in a biological sample (e.g., a blood sample) from a subject suspected of having the solid cancer.